Treatment with Imatinib in Patients with Wild-Type GIST
In this MEDtalk, Louise Bjørn Larsen presents a study that sought to determine the benefit of imatinib in patients with wild-type GIST. The results show that the median PFS on first-line imatinib was 6 months in advanced wild-type GIST, but with great variability.
Få tilgang
Hvis du er lege, sykepleier eller annen helsepersonell, kan du få tilgang til hele artikkelen ved å opprette en profil på BestPractice Nordic.
- Få tilgang
- Hvis du allerede har en profil: Logg in
